Sinopsis
MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company.Podcasts are intended for licensed adult healthcare professionals (HCPs). HCPs should exercise professional judgment in evaluating content, and confirm information before implementing treatment or practice-related changes. Podcasts do not provide medical advice to patients.
Episodios
-
![What are some of the more common adverse reactions associated with brentuximab vedotin?]()
What are some of the more common adverse reactions associated with brentuximab vedotin?
28/04/2017 Duración: 02minListen as Dr. Moskowitz discusses the more common adverse reactions associated with brentuximab vedotin and how they are most often managed.
-
![What are the different technologies used to assess cytogenetic risk status?]()
What are the different technologies used to assess cytogenetic risk status?
28/04/2017 Duración: 02minListen as Dr. Richter will discuss the different technologies used to assess cytogenetic risk status in your myeloma patient.
-
![What is meant by the term high-risk myeloma?]()
What is meant by the term high-risk myeloma?
28/04/2017 Duración: 02minListen as Dr. Richter will discuss the meaning of high-risk myeloma.
-
![Standard dosing and delivery of FOLFIRINOX]()
Standard dosing and delivery of FOLFIRINOX
28/04/2017 Duración: 02minListen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of FOLFIRNOX in patients with pancreatic cancer.
-
![The new FDA approval of pembrolizumab for cHL]()
The new FDA approval of pembrolizumab for cHL
23/03/2017 Duración: 04minListen as Dr. Anas Younes covers the new FDA approval of pembrolizumab for patients with cHL.
-
![Standard dosing and delivery of gemcitabine/nab-paclitaxel]()
Standard dosing and delivery of gemcitabine/nab-paclitaxel
23/03/2017 Duración: 02minListen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of gemcitabine/nab-paclitaxel in patients with pancreatic cancer.
-
![How do I diagnose chronic myelomonocytic leukemia (CMML)?]()
How do I diagnose chronic myelomonocytic leukemia (CMML)?
09/03/2017 Duración: 03minListen as Dr. Rami Komrokji explains how to diagnose chronic myelomonocytic leukemia (CMML).
-
![What tests should I obtain upfront at the time of MDS diagnosis?]()
What tests should I obtain upfront at the time of MDS diagnosis?
23/02/2017 Duración: 02minListen as Dr. Rami Komrokji discusses what tests to obtain upfront at the time of MDS diagnosis.
-
![How do I manage diarrhea in my patients taking ixazomib?]()
How do I manage diarrhea in my patients taking ixazomib?
07/02/2017 Duración: 01minListen as Dr. Donald Harvey explains how to manage diarrhea in patients taking ixazomib.
-
![What prophylactic antithrombotic agents are safe to use with lenalidomide?]()
What prophylactic antithrombotic agents are safe to use with lenalidomide?
07/02/2017 Duración: 01minListen as Dr. Donald Harvey explains which prophylactic antithrombotic agents are safe to use with lenalidomide.
-
![How do I manage renal dysfunction in my patient who is taking lenalidomide?]()
How do I manage renal dysfunction in my patient who is taking lenalidomide?
07/02/2017 Duración: 01minListen as Dr. Donald Harvey explains how he manages renal dysfunction in a patient who is taking lenalidomide.
-
![What do I do if my patient has an infusion reaction at home after receiving daratumumab?]()
What do I do if my patient has an infusion reaction at home after receiving daratumumab?
07/02/2017 Duración: 01minListen as Dr. Donald Harvey explains what he does if a patient has an infusion reaction at home after receiving daratumumab at the clinic.
-
![What do I do if my patient has an infusion reaction on elotuzumab, even after premedication?]()
What do I do if my patient has an infusion reaction on elotuzumab, even after premedication?
07/02/2017 Duración: 01minListen as Dr. Donald Harvey explains what he does if a patient has an infusion reaction on elotuzumab, even after premedication.
